• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.12% Nasdaq Up0.71%

    More On COX.PA



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Nicox SA (COX.PA)

    1.90 Down 0.01(0.37%) Apr 24, 11:35AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Nicox SA
    Drakkar 2 - B
    2405 route des Dolines
    Sophia Antipolis, 06906
    France - Map
    Phone: 33 4 97 24 53 00
    Fax: 33 4 97 24 53 99
    Website: http://www.nicox.com

    Index Membership:N/A
    Full Time Employees:124

    Business Summary 

    NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Nicox SA

    Key Executives 
    Mr. Michele Garufi , 61
    Co-Founder, Chairman and Chief Exec. Officer
    Ms. Elizabeth Robinson ,
    Co-Founder and Pres of The Nicox Research Institute Srl
    Mrs. Sandrine Gestin ,
    Fin. Director
    Dr. Michael V.W. Bergamini Ph.D.,
    Chief Scientific Officer and Exec. VP
    Dr. Gavin Spencer ,
    Exec. VP of Corp. Devel.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.